New hope for stomach cancer patients: drug combo aims to stop cancer coming back
NCT ID NCT07474324
First seen Mar 21, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study is for people with a certain type of stage III stomach cancer (HER2-positive) who have had surgery to remove the tumor. It tests whether adding the targeted drug disitamab vedotin to standard chemotherapy (SOX) can help keep the cancer from returning. About 124 participants will be randomly assigned to get either the combination or chemo alone, and researchers will track how long they stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GC/GEJC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.